Federal appeals court backs Lilly Zyprexa patent

12/26/2006 | NYTimes.com

The court affirmed a lower court ruling that Eli Lilly's schizophrenia drug patent is valid, rejecting efforts by the Ivax unit of Teva Pharmaceutical Industries and Dr. Reddy's Laboratories to overturn Lilly's 2011 patent expiration. The judges also said "Lilly did not fail to disclose information" to the patent office as the two rival drugmakers had argued.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC